생세포 캡슐화 시장(제2판) : 제조 기술 유형별, 캡슐화 방법별, 캡슐화 재료 유형별, 용도별, 치료 분야별, 지불 형태별, 주요 지역별 - 동향과 예측(-2035년)

Live Cell Encapsulation Market: Overview

As per Roots Analysis, the live cell encapsulation market is estimated to grow from USD 642 million in the current year to USD 1,787 million by 2035, at a CAGR of 12.1% during the forecast period, till 2035.

Live Cell Encapsulation Market: Growth and Trends

Live cell encapsulation is an advanced bioengineering technique in which viable cells are enclosed within semi-permeable polymeric membranes or hydrogel matrices (e.g., alginate). These systems allow selective exchange of oxygen, nutrients, growth factors, and therapeutic proteins while shielding cells from host immune responses, thereby supporting sustained cell viability and function without long-term immunosuppression.

First explored in the 1930s, the technology has evolved into a versatile platform for tissue engineering, regenerative medicine, controlled drug delivery, and cell-based therapies. It has shown strong potential in managing chronic conditions such as type 1 diabetes via encapsulated pancreatic islet transplantation, as well as neurological and metabolic disorders.

In live cell encapsulation, the focus is specifically on preserving the biological activity, proliferative capacity, and therapeutic secretion of living cells post-encapsulation. This has driven growing interest in regenerative medicine for targeted stem and progenitor cell delivery, and in emerging applications such as cancer immunotherapy and neuroprotection.

Given the multiple therapeutic and clinical advantages associated with the technology, including enhanced immune protection, prolonged therapeutic efficacy through sustained biomolecule secretion, improved cell survival, and reduced dependency on immunosuppressive treatments, the live cell encapsulation market is anticipated to witness significant growth during the forecast period. These advantages are expected to drive the growth of the live cell encapsulation market during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The growth of the live cell encapsulation market is primarily driven by the rising prevalence of chronic diseases, including diabetes, cancer, and autoimmune disorders, which has significantly increased the demand for advanced therapeutic approaches capable of improving treatment efficacy and supporting tissue regeneration. In response to this growing clinical need, substantial public and private sector investments in regenerative medicine and cell-based therapy research have accelerated the development of scalable and clinically viable encapsulation technologies. Additionally, continuous advancements in biomaterials, microfluidics, and nanoencapsulation technologies have enhanced cell viability, precision, stability, and biocompatibility, thereby strengthening the applicability of encapsulated cell systems across drug delivery, tissue engineering, and regenerative medicine. Collectively, these factors are positioning live cell encapsulation as a critical enabling technology for addressing unmet medical needs and driving its expanding adoption across the global healthcare market.

Market Challenges: Critical Barriers Impeding Progress

Despite its significant therapeutic potential, the live cell encapsulation market faces several challenges that may hinder its widespread adoption and commercialization. One of the primary constraints is the complexity associated with maintaining long-term cell viability, stability, and functionality within encapsulation systems, particularly under physiological conditions. Additionally, limitations related to biocompatibility, immune response, insufficient nutrient and oxygen diffusion, and inconsistent therapeutic output continue to pose technical barriers to clinical success. The market also faces challenges associated with large-scale manufacturing, process standardization, and high production costs, which can restrict scalability and commercial feasibility. Further, stringent regulatory requirements for cell-based therapies, coupled with lengthy approval timelines and limited long-term clinical data, create additional hurdles for market participants. Collectively, these scientific, operational, and regulatory challenges may impact the pace of innovation and broader adoption of live cell encapsulation technologies across the healthcare industry.

Live Cell Encapsulation Market: Key Insights

The report delves into the current state of the live cell encapsulation market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Live cell encapsulation technologies enable the precise delivery and prolonged functionality of living cells within biocompatible microenvironments for advanced therapeutic applications.

• The current landscape comprises of ~25 live cell encapsulation technologies designed to provide immune protection for transplanted cells, facilitating the sustained, localized delivery of therapeutic biomolecules.
• Close to 55% of the technologies use microencapsulation method, highlighting its dominance in the industry; notably, 40% of these technologies encapsulate cells targeting metabolic disorders, primarily type 1 diabetes.

• Majority of the agreements have been inked for the research and development of encapsulated cell therapies to target indications, such as type 1 diabetes, macular telangiectasia, and other chronic conditions.
• Close to 50% of the investments have been made in the last two years; notably venture capital emerged as the most prominent funding model, with Series A rounds accounting for 30% of its transactions.
• More than 20% of the patents related to cell encapsulation technologies have been published in a recent year; this is indicative of the rising focus on encapsulated cell therapies for the treatment of various disorders.
• Majority of the grants were awarded for Non-SBIR / STTR purposes; of these, a relatively larger proportion were research grants (R series) with type 5 emerging as the primary grants category.
• Given the rising prevalence of chronic diseases, coupled with rapid technological advancements, the live cell encapsulation market is anticipated to witness a steady growth in the foreseen future.

• Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.
• Carbohydrates sub-segment is estimated to capture most of the market share in the current year, due to the extensive use of starch, sucrose, and dextrose in drug formulations as stabilizers and bulking agents for biologics.
• Driven by the growing adoption of personalized medicine in the US, the live cell encapsulation market is poised to grow at a higher CAGR over the forecast period.

Live Cell Encapsulation Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Method of Encapsulation

• Microencapsulation
• Macroencapsulation
• Nanoencapsulation

By Type of Manufacturing Technique

• Electrostatic Dripping
• Simple Dripping
• Coaxial Airflow
• Rotating Disk Atomization
• Other Manufacturing Techniques

By Type of Encapsulation Material

• Alginate-based Microcapsules
• Chitosan
• Medical-grade Plastics
• Silica
• Cellulose Hydrogels
• Red Blood Cells

By Application Area

• Drug Delivery
• Immune Protection
• Probiotics and Functional Food
• Others

By Therapeutic Area

• Metabolic Disorders
• Oncological Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Cardiovascular Disorders
• Nephrological Disorders
• Other Disorders

By Type of Payment

• Upfront Payments
• Milestone Payments

By Key Geographical Regions

• North America
• US
• Canada
• Europe
• France
• Netherlands
• UK
• Belgium
• Asia-Pacific
• Japan
• Singapore

Live Cell Encapsulation Market: Key Segments

Market Share by Manufacturing Technique: Electrostatic Dripping Segment Holds the Largest Share

In the current year, the electrostatic dripping segment is expected to account for the largest share (~40%) of the live cell encapsulation market. The segment's dominance can be attributed to its capability to produce highly uniform microcapsules with narrow size distribution while maintaining high cell viability and minimizing shear stress during the encapsulation process. Additionally, the technique demonstrates strong compatibility with established regulatory requirements, further supporting its widespread adoption across clinical and research applications.

It is worth highlighting that the coaxial airflow segment is anticipated to witness the fastest growth, with a projected CAGR of 13.0% during the forecast period.

Market Share by Encapsulation Type: Microencapsulation Segment to Maintain Market Leadership

Currently, the microencapsulation segment is projected to capture the highest share (~60%) of the live cell encapsulation market and is further anticipated to expand at a comparatively higher CAGR of 11.8% over the forecast period. The segment's growth is primarily supported by its broad applicability across therapeutic areas, ability to enable controlled therapeutic release, and enhanced compatibility with a wide range of polymeric materials.

Market Share by Encapsulation Material: Alginate-based Microcapsules Segment to Generate Highest Revenue

Alginate-based microcapsules are expected to account for the largest share (~45%) of the live cell encapsulation market in the current year. This can be attributed to the material's high biocompatibility, low immunogenicity, cost-effectiveness, and ability to undergo ionic gelation under physiological conditions, thereby preserving cell viability. In addition, the medical-grade plastics segment is anticipated to witness the fastest growth during the forecast period, with a projected CAGR of 13.0%, driven by increasing demand for durable, scalable, and application-specific encapsulation materials.

Market Share by Application: Drug Delivery Segment to Dominate the Market

In the current year, the drug delivery segment is expected to hold the largest share of the live cell encapsulation market and is projected to grow at a CAGR of 12.3% during the forecast period. The segment's growth is primarily driven by the ability of encapsulated live cells to provide controlled and sustained release of therapeutic molecules, thereby enhancing treatment efficacy, reducing dosing frequency, and improving patient compliance.

Market Share by Therapeutic Area: Metabolic Disorders Segment to Lead the Market

The metabolic disorders segment is anticipated to account for the highest market share (~42%) in the current year and is expected to witness a CAGR of 12.3% during the forecast period. This growth is largely driven by the increasing global burden of metabolic diseases, particularly type 1 diabetes, alongside ongoing advancements in encapsulated islet cell and beta-cell therapies aimed at improving long-term disease management outcomes.

Regional Analysis

North America: Largest Regional Market

According to market projections, North America is expected to capture the largest share (~50%) of the live cell encapsulation market in the current year. The region's leadership can be attributed to its well-established healthcare and research infrastructure, robust public-private investments, and strong government support through organizations such as the NIH and FDA.

Additionally, the presence of a large number of leading biotechnology and pharmaceutical companies, coupled with favorable regulatory frameworks for cell-based therapies and increasing focus on personalized and regenerative medicine, continues to support regional market growth.

Asia-Pacific: Emerging High-Growth Region

The Asia-Pacific live cell encapsulation market is projected to witness the highest growth rate, with an anticipated CAGR of 11.84% through 2035. This growth is primarily driven by expanding healthcare infrastructure, cost-efficient clinical trial environments, increasing demand for advanced cell-based therapies, and growing awareness among healthcare providers and patients. Furthermore, strategic research and development initiatives across key markets, including China, Japan, India, and South Korea, are expected to further strengthen the region's market position during the forecast period.

Example Players in Live Cell Encapsulation Market

• Algorae Pharmaceuticals
• AltuCell
• Austrianova
• BIO INX
• Encellin
• Likarda
• Sphere Bio
• TreeFrog Therapeutics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Founder and Chief Executive Officer, Small Company, US
• Former Chief Executive Officer, Small Company, Israel

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer, Mid-sized Company, US
• Vice President, Medical Oncology, Large Company, US
• Chief Executive Officer, Mid-sized Company, US

Live Cell Encapsulation Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the live cell encapsulation market, focusing on key market segments, including [A] type of manufacturing technique, [B] type of encapsulation material, [C] application area, [D] type of payment, [E] and key geographical regions.
• Live Cell Encapsulation Market Landscape: A detailed assessment of the overall live cell encapsulation market landscape, along with information on several relevant parameters, such as [A] type of encapsulation method, [B] route of administration, [C] application area, [D] type of material used, [E] therapeutic area, [F] type of therapy, [G] year of establishment [H] company size, and [I] location of headquarters.
• Technology Competitiveness Analysis: An in-depth technology competitiveness analysis of various live cell encapsulation technologies based on various relevant parameters, such as [A] company strength, and [B] portfolio strength.
• Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations Analysis: An analysis of the partnerships that have been inked by stakeholders engaged in this domain. It includes a brief description of various partnership models and includes a detailed analysis of partnerships based on [A] year of partnership, [B] type of partnership, and [C] geographical analysis.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the the live cell encapsulation domain, encompassing seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing, based on several parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] geography, [E] most active players (in terms of number of funding instances and amount invested) and [F] leading investors (in terms of number of funding instances).
• Patent Analysis: A detailed analysis of the patents that have been filed / granted based on important parameters such as, [A] type of patent, [B] publication year, [C] application year, [D] number of granted patents and patent applications, [E] patent jurisdiction, [F] CPC symbols, [G] patent age, [H] type of applicant, and [I] individual patent assignees (in terms of size of intellectual property portfolio).
• Grants Analysis: An in-depth analysis of the grants received in the live cell encapsulation domain based on several factors such as [A] Year of Grant Award, [B] Amount Awarded, [C] Funding Institute Center, [D] Purpose of Grant Award, [E] Type of Grant Application and [F] Most Popular NIH Departments.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

• Which are the leading companies in the live cell encapsulation market?
• Which region dominates the live cell encapsulation market?
• What are the key trends observed in the live cell encapsulation market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by live cell encapsulation providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Overview of Cell Encapsulation
• 6.2. Type of Encapsulation Materials
• 6.3. Methods of Encapsulation
• 6.4. Application Area of Cell Encapsulation
• 6.5. Advantages of Cell Encapsulation Technologies
• 6.6. Future Trends

7. MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Live Cell Encapsulation Technologies: Overall Market Landscape
  • 7.2.1. Analysis by Type of Encapsulation Method
  • 7.2.2. Analysis by Route of Administration
  • 7.2.3. Analysis by Application Area
  • 7.2.4. Analysis by Type of Material Used
  • 7.2.5. Analysis by Therapeutic Area
  • 7.2.6. Analysis by Year of Establishment
  • 7.2.7. Analysis by Company Size
  • 7.2.8. Analysis by Location of Headquarters

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Methodology and Key Parameters
• 8.3.. Scoring Criteria
• 8.4. Overview of Peer Groups
• 8.5. Live Cell Encapsulation Technologies: Technology Competitiveness Analysis
  • 8.5.1. Live Cell Encapsulation Technologies: Provided by Players Headquartered in North America (Peer Group I)
    • 8.5.1.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group I)
  • 8.5.2. Live Cell Encapsulation Technologies: Provided by Players Headquartered in Europe (Peer Group II)
    • 8.5.2.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group II)
  • 8.5.3. Live Cell Encapsulation Technologies: Provided by Players Headquartered in Asia-Pacific and Rest of the World (Peer Group III)
    • 8.5.3.1. Live Cell Encapsulation Technologies: Overview of Players Providing Leading Technologies (Peer Group III)

9. COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. Algorae Pharmaceuticals
  • 9.2.1. Company Overview
  • 9.2.2. Technology Portfolio
  • 9.2.3. Recent Initiatives
• Similar details are presented for other companies mentioned below (based on information in the public domain)
• 9.3. Altucell
• 9.4. Austrianova
• 9.5. BIO INX
• 9.6. Encellin
• 9.7. Likarda
• 9.8. Sphere Bio
• 9.9. TreeFrog Therapeutics

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 16.2. Partnership Models
• 16.3. Live Cell Encapsulation: List of Partnerships and Collaborations
  • 16.3.1. Analysis by Year of Partnership
  • 16.3.2. Analysis by Type of Partnership
  • 16.3.3. Analysis by Year and Type of Partnership
  • 16.3.4. Key Technology: Analysis by Number of Partnerships
  • 16.3.5. Key Therapeutic Area: Analysis by Number of Partnerships
  • 16.3.6. Most Active Players: Analysis by Number of Partnerships
• 16.4. Analysis by Geography
  • 16.4.1. Local and International Agreements
  • 16.4.2. Intracontinental and Intercontinental Agreements

11. FUNDING AND INVESTMENTS

• 11.1. Chapter Overview
• 11.2. Funding Models
• 11.3. Funding Lifecycle Analysis
• 11.4. Investment Case: Risk and Returns
• 11.5. Live Cell Encapsulation: List of Funding and Investments
  • 11.5.1 Analysis by Year of Investment
  • 11.5.2. Analysis by Type of Funding
  • 11.5.3. Analysis by Year of Investment and Type of Funding
  • 11.5.4. Analysis by Year of Amount Invested
  • 11.5.5. Analysis by Amount Invested and Type of Funding
  • 11.5.6. Analysis by Geography
  • 11.5.7. Most Active Players: Analysis by Number of Instances
  • 11.5.8. Most Active Players: Analysis by Amount Invested
  • 11.5.9. Most Active Investors: Analysis by Number of Instances
  • 11.5.10. Most Active Investors: Analysis by Number of Instances

12. PATENT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Live Cell Encapsulation Market: Patent Analysis
  • 12.3.1. Analysis by Publication Year
  • 12.3.2. Analysis by Type of Patent
  • 12.3.3. Analysis by Type of Patent and Publication Year
  • 12.3.4. Analysis by Type of Applicant
  • 12.3.5. Analysis by Application Year
  • 12.3.6. Analysis by Patent Jurisdiction (Region)
  • 12.3.7. Analysis by Patent Jurisdiction (Country)
  • 12.3.8. Analysis by Patent Age
  • 12.3.9. Leading Industry Players: Analysis by Number of Patents
  • 12.3.10. Leading Non-Industry Players: Analysis by Number of Patents
  • 12.3.11. Leading Individual Assignees: Analysis by Number of Patents
  • 12.3.12. Analysis by CPC Symbols
• 12.4. Live Cell Encapsulation: Patent Benchmarking Analysis
• 12.5. Patent Valuation Analysis

13. GRANT ANALYSIS

• 13.1. Chapter Overview
• 13.2. Types of Grants
• 13.3. Types of Grants Applications
• 13.4. Key Factors for Consideration
• 13.5. Stages of Grants
• 13.6. Methodology and Key Parameters
• 13.7. Live Cell Encapsulation: Grants Analysis
  • 13.7.1. Analysis by Year of Grant Award
  • 13.7.2. Analysis by Amount Awarded
  • 13.7.3. Analysis by Funding Institute Center
  • 13.7.4. Analysis by Purpose of Grant Award
  • 13.7.5. Analysis by Type of Grant Application
  • 13.7.6. Analysis by Activity Code
  • 13.7.7. Analysis by Study Section Involved
  • 13.7.8. Analysis by Support Period
  • 13.7.9. Most Popular NIH Departments: Analysis by Number of Grants
  • 13.7.10. Type of Recipient Organizations: Analysis by Number of Grants
  • 13.7.11. Prominent Program Officers: Analysis by Number of Grants
  • 13.7.12. Popular Recipient Organizations: Analysis by Number of Grants
  • 13.7.13. Popular Recipient Organizations: Analysis by Grant Amount

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 14.1. Chapter Overview
• 14.2. Market Drivers
• 14.3. Market Restraints
• 14.4. Market Opportunities
• 14.5. Market Challenges
• 14.6. Conclusion

15. GLOBAL LIVE CELL ENCAPSULATION MARKET

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Global Live Cell Encapsulation Market, Forecasted Estimates (till 2035)
• 15.4. Roots Analysis Perspective on Market Growth
• 15.5. Scenario Analysis
  • 15.5.1. Conservative Scenario
  • 15.5.2. Optimistic Scenario
• 15.6. Key Market Segmentations

16. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF MANUFACTURING TECHNIQUE

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Live Cell Encapsulation Market: Distribution by Type of Manufacturing Technique
  • 16.3.1. Live Cell Encapsulation Market for Electrostatic Dripping, Forecasted Estimates (till 2035)
  • 16.3.2. Live Cell Encapsulation Market for Simple Dripping, Forecasted Estimates (till 2035)
  • 16.3.3. Live Cell Encapsulation Market for Coaxial Airflow, Forecasted Estimates (till 2035)
  • 16.3.4. Live Cell Encapsulation Market for Rotating Disk Atomization, Forecasted Estimates (till 2035)
  • 16.3.5. Live Cell Encapsulation Market for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
• 16.4. Data Triangulation and Validation

17. LIVE CELL ENCAPSULATION MARKET, BY METHOD OF ENCAPSULATION

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Live Cell Encapsulation Market: Distribution by Method of Encapsulation
  • 17.3.1. Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035)
  • 17.3.2. Live Cell Encapsulation Market for Microencapsulation, Forecasted Estimates (till 2035)
  • 17.3.3. Live Cell Encapsulation Market for Nanoencapsulation, Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF ENCAPSULATION MATERIAL

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Live Cell Encapsulation Market: Distribution by Type of Encapsulation Material
  • 18.3.1. Live Cell Encapsulation Market for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
  • 18.3.2. Live Cell Encapsulation Market for Chitosan, Forecasted Estimates (till 2035)
  • 18.3.3. Live Cell Encapsulation Market for Medical-grade Plastics, Forecasted Estimates (till 2035)
  • 18.3.4. Live Cell Encapsulation Market for Silica, Forecasted Estimates (till 2035)
  • 18.3.5. Live Cell Encapsulation Market for Cellulose Hydrogels, Forecasted Estimates (till 2035)
  • 18.3.6. Live Cell Encapsulation Market for Red Blood Cells, Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. LIVE CELL ENCAPSULATION MARKET, BY APPLICATION AREA

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Live Cell Encapsulation Market: Distribution by Application Area
  • 19.3.1. Live Cell Encapsulation Market for Drug Delivery, Forecasted Estimates (till 2035)
  • 19.3.2. Live Cell Encapsulation Market for Immune Protection, Forecasted Estimates (till 2035)
  • 19.3.3. Live Cell Encapsulation Market for Probiotics and Functional Food, Forecasted Estimates (till 2035)
  • 19.3.4. Live Cell Encapsulation Market for Others, Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. LIVE CELL ENCAPSULATION MARKET, BY THERAPEUTIC AREA

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Live Cell Encapsulation Market: Distribution by Therapeutic Area
  • 20.3.1. Live Cell Encapsulation Market for Metabolic Disorders, Forecasted Estimates (till 2035)
  • 20.3.2. Live Cell Encapsulation Market for Oncological Disorders, Forecasted Estimates (till 2035)
  • 20.3.3. Live Cell Encapsulation Market for Neurological Disorders, Forecasted Estimates (till 2035)
  • 20.3.4. Live Cell Encapsulation Market for Ophthalmic Disorders, Forecasted Estimates (till 2035)
  • 20.3.5. Live Cell Encapsulation Market for Cardiovascular Disorders, Forecasted Estimates (till 2035)
  • 20.3.6. Live Cell Encapsulation Market for Nephrological Disorders, Forecasted Estimates (till 2035)
  • 20.3.7. Live Cell Encapsulation Market for Other Disorders, Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. LIVE CELL ENCAPSULATION MARKET, BY TYPE OF PAYMENT

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Live Cell Encapsulation Market: Distribution by Type of Payment
  • 21.3.1. Live Cell Encapsulation Market for Milestone Payments, Forecasted Estimates (till 2035)
  • 21.3.2. Live Cell Encapsulation Market for Upfront Payments, Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. LIVE CELL ENCAPSULATION MARKET, BY GEOGRAPHY

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Live Cell Encapsulation Market: Distribution by Geography
  • 22.3.1. Antibody Contract Manufacturing Market in North America: Forecasted Estimates (till 2035)
    • 22.3.1.1. Antibody Contract Manufacturing Market in the US: Forecasted Estimates (till 2035)
    • 22.3.1.2. Antibody Contract Manufacturing Market in Canada: Forecasted Estimates (till 2035)
  • 22.3.2. Antibody Contract Manufacturing Market in Europe: Forecasted Estimates (till 2035)
    • 22.3.2.1. Antibody Contract Manufacturing Market in France: Forecasted Estimates (till 2035)
    • 22.3.2.2. Antibody Contract Manufacturing Market in Netherlands: Forecasted Estimates (till 2035)
    • 22.3.2.3. Antibody Contract Manufacturing Market in the UK: Forecasted Estimates (till 2035)
    • 22.3.2.4. Antibody Contract Manufacturing Market in Belgium: Forecasted Estimates (till 2035)
  • 22.3.3. Antibody Contract Manufacturing Market in Asia-Pacific: Forecasted Estimates (till 2035)
    • 22.3.3.1. Antibody Contract Manufacturing Market in Japan: Forecasted Estimates (till 2035)
    • 22.3.3.2. Antibody Contract Manufacturing Market in Singapore: Forecasted Estimates (till 2035)
• 22.4. Market Dynamics Assessment
  • 22.4.1. Penetration-Growth (P-G) Matrix
• 22.5. Data Triangulation and Validation

23. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 23.1. Live Cell Encapsulation Market in North America: Distribution by Type of Manufacturing Technique
  • 23.1.1. Live Cell Encapsulation Market in North America for Electrostatic Dripping, Forecasted Estimates (till 2035)
  • 23.1.2. Live Cell Encapsulation Market in North America for Simple Dripping, Forecasted Estimates (till 2035)
  • 23.1.3. Live Cell Encapsulation Market in North America for Coaxial Airflow, Forecasted Estimates (till 2035)
  • 23.1.4. Live Cell Encapsulation Market in North America for Rotating Disk Atomization, Forecasted Estimates (till 2035)
  • 23.1.5. Live Cell Encapsulation Market in North America for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
• 23.2. Live Cell Encapsulation Market in North America: Distribution by Method of Encapsulation
  • 23.2.1. Live Cell Encapsulation Market in North America for Microencapsulation, Forecasted Estimates (till 2035)
  • 23.2.2. Live Cell Encapsulation Market in North America for Macroencapsulation, Forecasted Estimates (till 2035)
  • 23.2.3. Live Cell Encapsulation Market in North America for Nanoencapsulation, Forecasted Estimates (till 2035)
• 23.3. Live Cell Encapsulation Market in North America: Distribution by Encapsulation Material
  • 23.3.1. Live Cell Encapsulation Market in North America for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
  • 23.3.2. Live Cell Encapsulation Market in North America for Chitosan, Forecasted Estimates (till 2035)
  • 23.3.3. Live Cell Encapsulation Market in North America for Medica-grade Plastics, Forecasted Estimates (till 2035)
  • 23.3.4. Live Cell Encapsulation Market in North America for Silica, Forecasted Estimates (till 2035)
  • 23.3.5. Live Cell Encapsulation Market in North America for Cellulose Hydrogels, Forecasted Estimates (till 2035)
  • 23.3.6. Live Cell Encapsulation Market in North America for Red Blood Cells, Forecasted Estimates (till 2035)
• 23.4. Live Cell Encapsulation Market in North America: Distribution by Application Area
  • 23.4.1. Live Cell Encapsulation Market in North America for Drug Delivery, Forecasted Estimates (till 2035)
  • 23.4.2. Live Cell Encapsulation Market in North America for Immune Protection, Forecasted Estimates (till 2035)
  • 23.4.3. Live Cell Encapsulation Market in North America for Probiotics and Functional Food, Forecasted Estimates (till 2035)
  • 23.4.4. Live Cell Encapsulation Market in North America for Others, Forecasted Estimates (till 2035)
• 23.5. Live Cell Encapsulation Market in North America: Distribution by Therapeutic Area
  • 23.5.1. Live Cell Encapsulation Market in North America for Metabolic Disorders, Forecasted Estimates (till 2035)
  • 23.5.2. Live Cell Encapsulation Market in North America for Oncological Disorders, Forecasted Estimates (till 2035)
  • 23.5.3. Live Cell Encapsulation Market in North America for Neurological Disorders, Forecasted Estimates (till 2035)
  • 23.5.4. Live Cell Encapsulation Market in North America for Ophthalmic Disorders, Forecasted Estimates (till 2035)
  • 23.5.5. Live Cell Encapsulation Market in North America for Cardiovascular Disorders, Forecasted Estimates (till 2035)
  • 23.5.6. Live Cell Encapsulation Market in North America for Nephrological Disorders, Forecasted Estimates (till 2035)
• 23.6. Live Cell Encapsulation Market in North America: Distribution by Type of Payment
  • 23.6.1. Live Cell Encapsulation Market in North America for Milestone Payments, Forecasted Estimates (till 2035)
  • 23.6.2. Live Cell Encapsulation Market in North America for Upfront Payments, Forecasted Estimates (till 2035)

24. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: EUROPE

• 24.1. Live Cell Encapsulation Market in Europe: Distribution by Type of Manufacturing Technique
  • 24.1.1. Live Cell Encapsulation Market in Europe for Electrostatic Dripping, Forecasted Estimates (till 2035)
  • 24.1.2. Live Cell Encapsulation Market in Europe for Simple Dripping, Forecasted Estimates (till 2035)
  • 24.1.3. Live Cell Encapsulation Market in Europe for Coaxial Airflow, Forecasted Estimates (till 2035)
  • 24.1.4. Live Cell Encapsulation Market in Europe for Rotating Disk Atomization, Forecasted Estimates (till 2035)
  • 24.1.5. Live Cell Encapsulation Market in Europe for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
• 24.2. Live Cell Encapsulation Market in Europe: Distribution by Method of Encapsulation
  • 24.2.1. Live Cell Encapsulation Market in Europe for Microencapsulation, Forecasted Estimates (till 2035)
  • 24.2.2. Live Cell Encapsulation Market in Europe for Macroencapsulation, Forecasted Estimates (till 2035)
  • 24.2.3. Live Cell Encapsulation Market in Europe for Nanoencapsulation, Forecasted Estimates (till 2035)
• 24.3. Live Cell Encapsulation Market in Europe: Distribution by Encapsulation Material
  • 24.3.1. Live Cell Encapsulation Market in Europe for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
  • 24.3.2. Live Cell Encapsulation Market in Europe for Chitosan, Forecasted Estimates (till 2035)
  • 24.3.3. Live Cell Encapsulation Market in Europe for Medica-grade Plastics, Forecasted Estimates (till 2035)
  • 24.3.4. Live Cell Encapsulation Market in Europe for Silica, Forecasted Estimates (till 2035)
  • 24.3.5. Live Cell Encapsulation Market in Europe for Cellulose Hydrogels, Forecasted Estimates (till 2035)
  • 24.3.6. Live Cell Encapsulation Market in Europe for Red Blood Cells, Forecasted Estimates (till 2035)
• 24.4. Live Cell Encapsulation Market in Europe: Distribution by Application Area
  • 24.4.1. Live Cell Encapsulation Market in Europe for Drug Delivery, Forecasted Estimates (till 2035)
  • 24.4.2. Live Cell Encapsulation Market in Europe for Immune Protection, Forecasted Estimates (till 2035)
  • 24.4.3. Live Cell Encapsulation Market in Europe for Probiotics and Functional Food, Forecasted Estimates (till 2035)
  • 24.4.4. Live Cell Encapsulation Market in Europe for Others, Forecasted Estimates (till 2035)
• 24.5. Live Cell Encapsulation Market in Europe: Distribution by Therapeutic Area
  • 24.5.1. Live Cell Encapsulation Market in Europe for Metabolic Disorders, Forecasted Estimates (till 2035)
  • 24.5.2. Live Cell Encapsulation Market in Europe for Oncological Disorders, Forecasted Estimates (till 2035)
  • 24.5.3. Live Cell Encapsulation Market in Europe for Neurological Disorders, Forecasted Estimates (till 2035)
  • 24.5.4. Live Cell Encapsulation Market in Europe for Ophthalmic Disorders, Forecasted Estimates (till 2035)
  • 24.5.5. Live Cell Encapsulation Market in Europe for Cardiovascular Disorders, Forecasted Estimates (till 2035)
  • 24.5.6. Live Cell Encapsulation Market in Europe for Nephrological Disorders, Forecasted Estimates (till 2035)
• 24.6. Live Cell Encapsulation Market in Europe: Distribution by Type of Payment
  • 24.6.1. Live Cell Encapsulation Market in Europe for Milestone Payments, Forecasted Estimates (till 2035)
  • 24.6.2. Live Cell Encapsulation Market in Europe for Upfront Payments, Forecasted Estimates (till 2035)

25. LIVE CELL ENCAPSULATION MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 25.1. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Type of Manufacturing Technique
  • 25.1.1. Live Cell Encapsulation Market in Asia-Pacific for Electrostatic Dripping, Forecasted Estimates (till 2035)
  • 25.1.2. Live Cell Encapsulation Market in Asia-Pacific for Simple Dripping, Forecasted Estimates (till 2035)
  • 25.1.3. Live Cell Encapsulation Market in Asia-Pacific for Coaxial Airflow, Forecasted Estimates (till 2035)
  • 25.1.4. Live Cell Encapsulation Market in Asia-Pacific for Rotating Disk Atomization, Forecasted Estimates (till 2035)
  • 25.1.5. Live Cell Encapsulation Market in Asia-Pacific for Other Manufacturing Techniques, Forecasted Estimates (till 2035)
• 25.2. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Method of Encapsulation
  • 25.2.1. Live Cell Encapsulation Market in Asia-Pacific for Microencapsulation, Forecasted Estimates (till 2035)
  • 25.2.2. Live Cell Encapsulation Market in Asia-Pacific for Macroencapsulation, Forecasted Estimates (till 2035)
  • 25.2.3. Live Cell Encapsulation Market in Asia-Pacific for Nanoencapsulation, Forecasted Estimates (till 2035)
• 25.3. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Encapsulation Material
  • 25.3.1. Live Cell Encapsulation Market in Asia-Pacific for Alginate-based Microcapsules, Forecasted Estimates (till 2035)
  • 25.3.2. Live Cell Encapsulation Market in Asia-Pacific for Chitosan, Forecasted Estimates (till 2035)
  • 25.3.3. Live Cell Encapsulation Market in Asia-Pacific for Medica-grade Plastics, Forecasted Estimates (till 2035)
  • 25.3.4. Live Cell Encapsulation Market in Asia-Pacific for Silica, Forecasted Estimates (till 2035)
  • 25.3.5. Live Cell Encapsulation Market in Asia-Pacific for Cellulose Hydrogels, Forecasted Estimates (till 2035)
  • 25.3.6. Live Cell Encapsulation Market in Asia-Pacific for Red Blood Cells, Forecasted Estimates (till 2035)
• 25.4. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Application Area
  • 25.4.1. Live Cell Encapsulation Market in Asia-Pacific for Drug Delivery, Forecasted Estimates (till 2035)
  • 25.4.2. Live Cell Encapsulation Market in Asia-Pacific for Immune Protection, Forecasted Estimates (till 2035)
  • 25.4.3. Live Cell Encapsulation Market in Asia-Pacific for Probiotics and Functional Food, Forecasted Estimates (till 2035)
  • 25.4.4. Live Cell Encapsulation Market in Asia-Pacific for Others, Forecasted Estimates (till 2035)
• 25.5. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Therapeutic Area
  • 25.5.1. Live Cell Encapsulation Market in Asia-Pacific for Metabolic Disorders, Forecasted Estimates (till 2035)
  • 25.5.2. Live Cell Encapsulation Market in Asia-Pacific for Oncological Disorders, Forecasted Estimates (till 2035)
  • 25.5.3. Live Cell Encapsulation Market in Asia-Pacific for Neurological Disorders, Forecasted Estimates (till 2035)
  • 25.5.4. Live Cell Encapsulation Market in Asia-Pacific for Ophthalmic Disorders, Forecasted Estimates (till 2035)
  • 25.5.5. Live Cell Encapsulation Market in Asia-Pacific for Cardiovascular Disorders, Forecasted Estimates (till 2035)
  • 25.5.6. Live Cell Encapsulation Market in Asia-Pacific for Nephrological Disorders, Forecasted Estimates (till 2035)
• 25.6. Live Cell Encapsulation Market in Asia-Pacific: Distribution by Type of Payment
  • 25.6.1. Live Cell Encapsulation Market in Asia-Pacific for Milestone Payments, Forecasted Estimates (till 2035)
  • 25.6.2. Live Cell Encapsulation Market in Asia-Pacific for Upfront Payments, Forecasted Estimates (till 2035)
• *Detailed information on Chapters 25-27 is available in the Excel Data Packs shared along with the report**

26. PORTER'S FIVE FORCES

• 26.1. Chapter Overview
• 26.2. Methodology and Assumptions
• 26.3. Key Parameters
  • 26.3.1. Threat of New Entrants
  • 26.3.2. Bargaining Power of Buyers
  • 26.3.3. Bargaining Power of Service Providers
  • 26.3.4. Threats of Substitute Products
  • 26.3.5. Rivalry Among Existing Competitors
• 26.4. Concluding Remarks

27. CONCLUDING REMARKS

28. EXECUTIVE INSIGHTS

29. APPENDIX I: TABULATED DATA

30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS